The progress of drug research stops in the face of monopolies

In the era of technological medicine, methodologies have allowed the diagnosis of diseases in advance, more accurately and more quickly. Have the medicines we take to combat them kept up?

Today over two billion people live without access to medicine. The cause of this global crisis are drug prices, even in the wealthiest countries. An estimated 34 million Americans have lost an acquaintance in the past five years, not because the treatment didn't exist, but because they couldn't afford it. Rising drug costs are pushing families to mortgage their homes, bankrupt old people and parents towards crowdfunding treatments for their critically ill children. There are many reasons for this crisis, but one is the outdated patent system that states like America are trying to export to the rest of the world. The original intention behind the patent system was to motivate people who invented new medicine by rewarding them with a time-limited monopoly. But today, this intention has been distorted. Corporations have teams of lawyers and lobbyists whose only job is to extend patent protection for as long as possible. Patents on drugs have grown incredibly in a very short period of time: between 2006 and 2016 they have doubled. But the real consideration is that the vast majority of medicines associated with the new drug patents are not actually new. Almost eight out of 10 are for existing ones, such as insulin or aspirin.

In a recent survey conducted by I-MAK, a non-profit organization for drug access, on the 12 best-selling drugs in America, it was discovered that, on average, there are 125 patents filed on each medicine. The higher the number of patents that a company files, the longer their monopoly unravels. And without anyone to compete with, they can set prices as they wish. And as it comes to medicines, there is no choice but to pay.

The patent wall is a strategy for blocking competition. Not for the maximum 14 years initially foreseen in the past or for the 20 years allowed by law today, but for 40 or more years. In the meantime, the prices of these drugs have continued to rise by up to 68% since 2012, and people are struggling or even dying because they cannot afford the medicines.

Now, it's not about making the pharmaceutical industry the bad guy. The most correct reflection is whether the system we have designed to promote progress is actually working as expected. drug research has been ousted in favor of the legal strategy, progress has stopped. It's like giving 100 Pulitzer Prizes to an author for the same book. The paradigm shift lies in creating a modern patent system to meet the needs of a 21st century company. And to do this, it is necessary to reinvent the patent system to serve the public, not just companies.

The co-founder of I-MAK Priti Krishtel proposes 5 reforms:

  • Stop issuing so many patents. Under the Kennedy administration, in an attempt to curb rising drug costs, a member of Congress for the state of Tennessee proposed the idea that in order to obtain a new patent for the same drug, the modified version would be due. be significantly better therapeutically for patients. But due to intense lobbying, this idea has never seen the light of day. This shouldn't be controversial. As a company, we reserve big prizes for great ideas. Still, we distribute patents worth billions for small, almost insignificant changes.
  • Secondly, the financial incentives of the Patent Office need to be changed. To date, the revenue of the patent office is directly related to the number of patents it grants. It is as if private prisons are being paid more to hold more people. It is natural that this leads to more incarceration. It is as if doctors were being paid more to prescribe medications. It is natural that this leads to an overmedicalization of patients. The same goes for patents.
  • Third, give access to public participation. Right now, the patent system is like a black box. It's a two-way conversation between the patent office and the industry. The patent office must be opened, made clear and transparent. A dynamic center for learning and ingenuity, managed not only by technical experts and bureaucrats, but also by relevant voices in the field of public health with a passion for science. Citizens would obtain accessible information on complex technologies such as artificial intelligence or genetic editing, allowing greater knowledge and understanding that results in participation in political conversations that directly affect public health and private life.
  • Fourthly, you need to get the right of objection in court. Now, after the granting of a patent, the public has no legal value. Only legal entities with a commercial interest (other pharmaceutical companies) have this right. The I-MAK organization also saved lives in India in 2006, to legally challenge patents on drugs against HIV, at a time when the epidemic broke out where hundreds of thousands were dying, because the prices some medicines were out of range. I-MAK activists managed to cut drug prices by 87%. With just three drugs, they managed to save the Indian health system half a billion dollars, cure and prevent cases for millions of individuals.
  • Finally, a stronger supervisory body is needed, an independent unit that can act as a public lawyer, which regularly monitors the activities of the patent office. If a unit like this existed, it would have avoided the scandal that involved the Silicon Valley company Theranos in 2017. Before getting so many patents for blood tests and getting a nine billion dollar stock exchange valuation, when in there was actually no kind of innovation.

And this type of responsibility will become increasingly urgent in the future. Only now are important questions being asked about whether companies can sell patient data that is used to create new therapies that we don't need. The key thing to keep in mind is that it's not a game between patent holders and activists. It is such a profound misunderstanding that it affects people; the right to safeguard inventions and the right to life.

Share the post

  • L'Autore

    Andrea Radaelli

    Come si inizia una descrizione di sé stessi? Proviamo dall’inizio… sono nato il 20 ottobre 1997, fin da subito sono stato un soggetto particolarmente vivace e non sempre facile. L’aggettivo che più spesso hanno utilizzato i miei parenti, i miei amici e le persone che mi stanno accanto per descrivermi è senza dubbio ‘curioso’.

    Curioso del mondo, di come funziona e dei nostri effetti su di esso. Non solo in campo scientifico ma anche economico e geopolitico. Mi interesso di tutto ciò che ha un outcome positivo e propositivo, soprattutto nella sanità e nelle nuove tecnologie.

    Curioso per le mie opinioni molto forti e per certi aspetti critiche sulla società, che a volte diventano i miei limiti. Alcune di queste sono che la conoscenza è faticosa ma rende liberi, che l’ignoranza nell’era dell’informazione è una scelta consapevole e che l’uguaglianza (dare alle persone le stesse cose) è un paradigma da superare con l’equità (dare alle persone le stesse opportunità).

    Curioso anche per la mia personalità; ho delle idee molto ben determinate, sono un convinto ‘individualista sociale’. Cioè che ognuno di noi deve prima crescere e acculturarsi secondo le proprie inclinazioni per poi poter entrare in un gruppo di lavoro per poterlo arricchire della sua prospettiva.

    Curioso per le mie scelte, dopo le medie ho scelto un liceo ad indirizzo artistico nonostante i miei professori spingessero per un liceo classico. Durante questi cinque anni ho avuto modo di viaggiare per l’Italia e scoprire gli incredibili siti dell’UNESCO. Ho viaggiato anche in Europa nelle maggiori capitali e mi sono innamorato dell’Unione Europea. Ho compreso quanto siamo fortunati del far parte di comunità internazionale e delle straordinarie opportunità che offre. Finite le superiori, ho scelto di studiare lingue applicate all’ambito economico nel CdL di ‘Scienze per la Mediazione Linguistica e Culturale’, un’università ricca di diversità; di nazionalità diverse, di lingue diverse e di culture diverse. L’opportunità che mi sono state date dall’essere a contatto con tutta questa ricchezza mi hanno spinto a ricercare un percorso decisamente più strutturato ed innovativo; la scienza dei dati che spesso utilizzo nei miei articoli che, troppo spesso, consegno in ritardo.

    Di Mondo Internazionale mi ha colpito la potenzialità, la composizione giovane e il dinamismo. Le aree tematiche nel quale mi trovo a mio agio sono economia, sanità, ambiente e innovazione. Il progetto di ‘Tra Scienza e Conoscenza’ è quello con cui collaboro maggiormente e, soprattutto grazie alla pazienza dei miei collaboratori, mi trovo veramente bene.


Sections Nutrition Medical Research Health & Wellness


medicina tecnologica malattie monopolio

You might be interested in


The progress of drug research stops in the face of monopolies

Andrea Radaelli
Log in to your Mondo Internazionale account
Forgot Password? Get it back here